Epizyme’s sarcoma drug tazemetostat faces key vote from FDA advisersEpizyme’s sarcoma drug tazemetostat is set to go before an influential FDA advisory committee today, following a mixed Share XEpizyme’s sarcoma drug tazemetostat faces key vote from FDA advisershttps://pharmaphorum.com/news/epizymes-sarcoma-drug-tazemetostat-faces-key-vote-from-fda-advisers/
